Orange, I cant say anything about SYN... I don't know much about the investment. I was looking at the chart for a colleague. Chart picture has the look of waiting for a new larger rally. would there be any good news coming ?
- Expect to share additional results regarding several exploratory endpoints from Phase 2b proof-of-concept clinical trial designed to evaluate SYN-004’s (ribaxamase) ability to protect the gut microbiome from opportunistic bacterial infections and prevent the emergence of antimicrobial resistance (AMR) in the gut microbiome (4Q 2017)
- Plan to continue collaborative discussions with the FDA to solidify details and components of the drug development plan and regulatory pathway towards marketing approval for SYN-004 (ribaxamase) (1Q 2018)
- Plan to initiate Phase 3 clinical trial(s) (2018)
Worth mentioning they have BTD designation for SYN-004. Patience is golden with this one imo.
News 
Market Data 
Discover 
